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Condensation and short version of title 
 
Short title: 
Persistent fimbrial tissue on ovarian surface 
Condensation: 
Residual fimbrial tissue remains on the ovarian surface in a significant proportion of cases 
post salpingectomy. This could serve as a site for ovarian carcinogenesis. 
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Abstract 
Background 
Salpingectomy is recommended as a risk-reducing strategy for epithelial tubo-ovarian 
cancer. The gold standard procedure is complete tubal excision.  
Objective 
To assess the presence of residual fimbrial/tubal tissue on ovarian surfaces following 
salpingectomy. 
Design 
Prospective analysis of patients undergoing salpingo-oophorectomy +/- hysterectomy for 
benign indications, early cervical cancer or low risk endometrial cancer at a UK National 
Health Service Trust. Salpingectomy +/- hysterectomy was performed initially, followed by 
oophorectomy within the same operation. Separately retrieved tubes and ovaries were 
serially sectioned and completely examined histologically.  The main outcome measure was 
histologically identified fimbrial/ tubal tissue on ovarian surface. Chi-square/Fisher’s exact 
tests evaluated categorical variables (SPSS-23).  
Results 
25 consecutive cases (mean age= 54.8 years (SD=5.0), comprising 41 adnexae (9= unilateral,  
16= bilateral) were analysed. 17 (68.0%), 5 (20.0%) and 3 (12.0%), procedures were 
performed by consultant gynaecologists, subspecialty/specialist trainees and consultant 
gynaecological oncologists respectively. 12/25 (48.0%) were laparoscopic and 13/25 (52.0%) 
involved laparotomy.  4/25 (16.0%, CI: 4.5%, 36.1%) patients or 4/41 (9.8%, CI: 2.7%, 23.1%) 
adnexae showed residual microscopic fimbrial tissue on the ovarian surface.  
Tubes/ ovaries were free of adhesions in 23 cases. Two cases had dense adnexal adhesions 
but neither had residual fimbrial tissue on the ovary. Residual fimbrial tissue was not 
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significantly associated with surgical route or experience; (consultant= 3/20 (15%), trainee= 
1/5 (20%), p=1.0).   
Conclusion 
Residual fimbrial tissue remains on the ovary following salpingectomy in a significant 
proportion of cases and could impact the level of risk-reduction obtained.  
Keywords  
High-grade serous carcinoma, ovarian cancer, ovarian surface, prophylactic surgery, residual 
fimbrial tissue, salpingectomy 
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Introduction 
Ovarian cancer (OC), principally its commonest histotypes, high-grade serous ovarian 
carcinoma (HGSC), is the leading cause of deaths from gynaecological cancers. OC is 
responsible for 4271 deaths/year in the UK, 42,700 deaths/year in Europe, 14240 
deaths/year in the USA and 152,000 deaths/year worldwide.1, 2 Despite advances in 
treatment there have been only marginal improvements in survival over the last 20 years.3 
Screening for this disease has not yet been shown to reduce mortality,4 leading to a drive for 
exploring newer prevention strategies.  
 
There is increasing evidence that the fallopian tube plays a central role in the origin of 
HGSC5-9 and serous tubal intraepithelial carcinoma (STIC) is established as a precursor lesion, 
present as a continuum with early tubal carcinomas, supporting transition from insitu to 
invasive cancer.10 We too have previously seen high-grade serous carcinoma (HGSC) 
involving fimbrial tissue on the ovarian surface (Figure-1). The growing evidence in favour of 
tubal origin of epithelial ovarian cancer has led to opportunistic bilateral salpingectomy 
(OBS) being recommended as an OC prevention strategy for premenopausal women who 
have completed their family and are undergoing tubal sterilisation or other benign 
gynaecological surgery.9 Tubal ligation and hysterectomy itself are associated with a 
reduction in OC risk.11 Supporting evidence for salpingectomy also comes from a 35%-42% 
reduction in OC risk reported on retrospective analysis of Swedish12 and Danish13 population 
based data sets, although in the Swedish study this was limited by lack of control for the 
contraceptive pill and the number of OC cases in the bilateral salpingectomy subgroups is 
small. Additionally in high risk women (e.g. BRCA carriers) ongoing studies are evaluating the 
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feasibility of premenopausal early salpingectomy and delayed oophorectomy as an ovarian 
function preserving two-step method for preventing OC. 
 
Some centres have changed clinical protocols to incorporate OBS into practice.14 Recent 
guidelines from the American Congress of Obstetricians and Gynecologists (ACOG)15 and 
Society of Gynecologic Oncology (SGO)16 recommend OBS be considered as an OC 
prevention strategy whilst also highlighting the need and importance for further trials to 
confirm the validity and benefit of this approach. We found that around 30% of UK clinicians 
are currently undertaking this procedure, while 89% would support a prospective trial.17  
Prospective data on the level of reduction in OC risk following salpingectomy are lacking. 
Additionally, the presence of residual tubal tissue on the ovarian surface following 
salpingectomy has not been prospectively evaluated. This could have potential implications 
for the level of risk reduction. We present data which prospectively reports on the presence 
of residual microscopic fimbrial tissue on the ovarian surface following salpingectomy. 
 
Methods:  
Patients 
Patients undergoing salpingo-oophorectomy +/- hysterectomy (laparoscopic or laparotomy) 
for benign indications, early cervical cancer or low-risk endometrial cancer were included. 
Patients with other pelvic malignancy, previous bilateral salpingectomy or bilateral 
oophorectomy were excluded.  
Salpingectomy Procedure 
The surgical procedure was undertaken in two steps within the same operation. 
Salpingectomy with or without hysterectomy (as indicated) was performed initially. This was 
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followed by bilateral oophorectomy as a second step within the same operation. Thus 
overall each patient had the same planned elective surgical procedure. The ovaries and 
tubes removed were sent in separately labelled pots: right tube, left tube, right ovary and 
left ovary. In some specimens, fallopian tubes remained attached to the uterus. Intra-
operative findings were documented using a customised form (supplementary table-1). 
Procedures were undertaken by consultant gynaecologists, consultant gynaecological 
oncologists and specialist or subspecialty trainees in gynaecological oncology. 
Histopathological examination of fallopian tubes and ovaries:  
Histological assessment was undertaken by a team of two gynaecological pathologists at the 
Royal London Hospital (NS and AF). Fallopian tubes were serially sectioned according to SEE-
FIM protocol (Sectioning and Extensively Examining the FIMbriated end of the fallopian 
tube).18 This protocol entails lengthwise sectioning of the fimbriated portion of the tube to 
maximize exposure of the tubal plicae with maximum serial sectioning of no more than 2-
3mm apart. The ovaries were also serially sectioned in their entirety and examined for 
presence of any remnant tubal tissue. The uterus where removed was assessed in 
accordance with routine histological protocol and the surgical indication. Histological slides 
stained with hematoxylin and eosin (H&E) were reviewed by both gynaecological 
pathologists. Confirmation and agreement by both pathologists was obtained in cases 
where fimbrial tissues were identified.  
 
Consecutive patients fulfilling the inclusion criteria within the Barts Health Cancer Network 
were identified between 1st October 2015 and 5th January 2016. This was done through 
close liaison between gynaecological oncology team, benign gynaecology consultants linked 
to the cancer network, administrative assistants as well as review of the online surgical diary 
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at Royal London Hospital. Of the 39 consecutive cases identified, 25 were finally suitable for 
analysis. 14 were excluded for the following reasons: (a) protocol deviation, with all 
specimens sent to the pathology lab in error in the same single pot (n=4); (b) planned case 
not performed as patient not fit on the day (n=4); (c) case not deemed suitable by operating 
surgeon due to significant adnexal pathology and surgical difficulty (n=6).  
This project was approved by the Clinical Effectiveness Unit (CEU) and Research and 
Development (R&D) team at Royal London Hospital, Barts Health NHS Trust (UK) as a clinical 
effectiveness audit (Project ID=5855). Permission for data analysis and submission for 
publication was given. This project was not funded through any grant. It is supported by the 
Department of Gynaecological Oncology, Royal London Hospital, London, UK and Barts 
Cancer Institute, Queen Mary University, London, UK. 
 
Assuming a null hypothesis or gold standard of ‘1’% specimens having residual tubal tissue, 
for a power of 80% and α=0.05, the sample size for identifying 10% specimens with residual 
tubal tissue is 25. Baseline characteristics were described using descriptive statistics. Chi-
square/Fisher’s exact and Mann-Whitney tests were used to evaluate differences between 
categorical and continuous variables respectively. Statistical analyses were performed on 
SPSS version 23 (IBM Corp 2010 Armonk, NY).  
 
Results 
Forty-one adnexae (9 unilateral and 16 bilateral) from 25 patients were analysed for 
histological presence of tubal fimbrial tissue on the ovary.  The mean age of patients was 
54.8 years (SD=5.0, range 45-64). Table-1 describes the indications for surgery. A summary 
of all the cases, including procedure undertaken, age, presence of intra-operative adhesions 
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and fimbrial tissue on the ovary at histology, is given in Table-2. Twelve (48.0%) and 13 
(52.0%) cases were carried out by laparoscopy and laparotomy respectively. All patients 
undergoing hysterectomy had hysterectomy with salpingectomy (tubes attached to the 
uterus) followed by oophorectomy as a two-step procedure. Consultant gynaecologists, 
subspecialty or specialist trainees and consultant gynaecological oncologists performed 
17/25 (68.0%), 5/25 (20.0%) and 3/25 (12.0%) procedures respectively. Cases were 
randomly allocated depending on surgical list availability. The final histology following 
surgery was reported as benign in 19/25 (76%) cases and malignant in 6/25 (24%) cases 
(Table-2).  No intra- or post-operative complications (based on Dindo-Clavien 
classification)19 occurred. The mean blood loss for our study population was 230mls 
(SD=168.3). The mean duration of hospital stay was 2.2 days (SD=1.0).  
  
Residual microscopic fimbrial tissue was found on the ipsilateral ovarian surface in four of 
25 patients (16.0%, CI: 4.5%,36.1%) or 4/41 (9.8%, CI: 2.7%,23.1%) adnexae removed. This is 
illustrated in Figure-2. An objective measurement to quantify the residual fimbrial  tissue in 
the four cases showed, the tissue measured (a) 3mm x 2mm x 1mm; (b) 2mm x 2mm x 
2mm; (c) 4mm x 2.5mm x 2 mm; (d) 3mm x 2mm x 1.5 mm in the four cases respectively. All 
four cases occurred in women undergoing abdominal hysterectomy. There were two cases 
(one adnexa in each case) where dense adhesions were encountered intra-operatively. In 
one case fimbriae were densely adherent to the right ovary, with 2/3 of its fimbrial portion 
enclosed in adhesions. The other had involvement of the whole tube including the fimbrial 
portion being densely adherent to the ovary. However, in both cases the tubes were 
surgically separated from the ovaries and neither ovary showed any residual fimbrial tissue 
on the ovarian surface. Intraoperatively, there were no adhesions between the tube and 
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ovary in any of the other 23 patients. The fimbriae lay completely separately and were not 
found to touch the ovary (no fimbria ovarica seen) in any of these 23 patients.  
The presence of fimbrial tissue was not significantly affected by the route of surgery 
(laparoscopic/ laparotomy) or experience of the surgeon. Although all fours cases with 
residual fimbrial tissue were performed by laparotomy, this association is not statistically 
significant (p=0.096) and given small numbers we feel it is probably due to  chance. We 
don’t think this relates to surgical technique. One of these four was performed by a 
specialist trainee (1/5) under direct supervision and three (3/20) by experienced consultant 
gynaecologists (p=1.0).  
Comment 
Main Findings 
We found that 16% women or 10% adnexae had fimbrial tissue implants on the ipsilateral 
ovarian surface despite salpingectomy. Moreover these did not occur in cases with 
adhesions or any form of adherence of fimbriae/tube to the ovary. The ovaries lay 
completely separate and well away from the fallopian tubes in these cases. While surgical 
removal of an adherent tube (either due to adhesions or fimbria ovarica) may result in 
residual tubal/fimbrial tissue on the ovarian surface, these findings of implants on non-
adherent ovaries in a considerable proportion of women were completely unexpected. This 
could represent a potential site for ovarian carcinogenesis. To the best of our knowledge 
this is the first prospective series evaluating the presence of residual fimbrial tissue which 
may remain after salpingectomy. We searched Medline and Embase databases using free 
text and thesaurus-based search terms:  
11 
 
Salpingectomy, fimbria, fimbriae, fimbrial tissue, residual tubal tissue, ovary surface, tubal 
implants, fimbrial implants, uterine tubal mucosa, salpingectomy and ovary.  We used three 
strategies:  
1. ((‘Salpingectomy’) AND (‘fimbria’ OR ‘fimbriae’ OR ‘residual fimbrial tissue’ OR ‘residual 
tubal tissue’ OR ‘ovary surface’))      
2. ((‘tubal implants’ OR ‘fimbrial implants’ OR ‘uterine tubal mucosa’) AND 
(‘salpingectomy’))  
3. ((‘tubal implants’ OR ‘fimbrial implants’ OR ‘uterine tubal mucosa’) AND (‘ovary’)) 
Details of the search strategy are given in supplementary table-2. Overall 125 abstracts were 
reviewed by two co-authors. No reports describing the presence of fimbrial tissue post 
salpingectomy were identified. 
 
Strengths and Limitations 
Our paper has several advantages, such as the prospective nature of this work, use of a 
serial sectioning histopathological protocol with strict pathological review by two 
experienced pathologists, as well as inclusion of both laparoscopic and laparotomy based 
surgical approaches. We excluded cases with benign or malignant adnexal pathology which 
may have the propensity to increase false positive findings. All our cases included 
macroscopic normally looking tubes and ovaries. A limitation is the small number of cases in 
our series. Additionally, four cases were excluded due to error in transport of histological 
specimens. However this series has sufficient power to detect a ≥10% incidence of residual 
fimbrial tissue, a level found in this study.  
 
12 
 
Interpretation / Meaning: 
These findings are of crucial if not of critical importance as well as hypothesis generating. 
We suggest that clumps of fimbrial tissue may be shed from the fimbrial end of the tubes, 
some of which implant on the ovarian surface. However, it is also possible that fimbrial 
tissue adheres to the ovarian surface over repeated ovulatory episodes, and then may 
become detached from the tube. We hypothesise that this residual tissue may also undergo 
malignant transformation (just like fimbria present in the tube) following geno-toxic injury 
over a period of time. The presence of STIC/invasive lesions in the tubal tissue of women 
with OC reported in various series varies from 11-60%.20-30 Our findings support the possible 
tubal origin of OC despite absence of STIC lesions in the tube as malignant transformation 
could have started in the fimbrial implants on the ovarian surface without involving the rest 
of the tube. It could also explain a recent finding of some STICs being genomically different 
to co-existent serous OC and thus metastasize.31 It also corroborates the hypothesis that OC 
may arise in cortical inclusion cysts, as the fimbrial tissue found on the surface of the ovary, 
could get incorporated into these cysts and undergo subsequent malignant 
transformation.32 Alternatively, the ovarian surface in conjunction with the fimbrial implant 
may rupture during ovulation and subsequently predispose fimbriae to malignant 
transformation. Ovarian surface epithelium at junction areas may contain a novel stem cell 
niche that is responsible for surface epithelium regeneration and subsequently prone to 
malignant transformation.33 
We speculate that these fimbrial tissues may also be shed and implant on the peritoneal 
surface (just as on the ovary) but currently there is no conclusive histological evidence to 
support this possibility. However, if true, this could explain the occurrence of primary 
peritoneal cancer in low-risk women as well as in 4% BRCA1/BRCA2 carriers despite bilateral 
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salpingo-oophorectomy.34 It may also explain the presence of malignant peritoneal cytology 
found in some women at risk-reducing surgery without a co-existent invasive cancer/STIC 
lesion.34 
 
The tubo-peritoneal junction (TPJ) has been suggested as a likely site for origin of serous OC, 
with STICs found at and in the immediate vicinity of the TPJ.35 Transitional metaplasia is 
found in up to 26% of TPJs and it has been proposed that adnexal peritoneum, Fallopian 
tube epithelium and ovarian surface epithelium (OSE) should be viewed as a continuous 
unit36. Our data indicate another potential site for STICs which lies outside the TPJ, but 
within fimbriae shed on the ovarian surface. We found fimbrial implants in both pre-
menopausal and post-menopausal women. However, a number of questions remain 
unanswered, including the precise mechanism and timing of shedding of fimbrial tissue as 
well as the duration for which this tissue may persist on the ovarian surface, and the lead 
time to malignant transformation after implantation on the ovary. We do not know if these 
fimbriae are shed due to hormonal or cell non-autonomous mechanisms occurring 
predominantly in the pre-menopausal period with fimbrial tissue subsequently remaining on 
the ovaries in postmenopausal women or whether this is an active process that also occurs 
after the menopause. These issues need to be addressed through future research.   
According to the tubal hypothesis it is fimbrial tissue which is the main cell of origin of 
HGSC. However, not all HGSC arise within the tube.37 Recent genomic analysis of co-existent 
STIC and serous OC cases indicated STICs were precursors in only 50% cases.31 Our findings 
thus may also help explain why salpingectomy prevents only a proportion of epithelial OC 
and will not prevent all cases. The issue of undertaking OBS in routine practice or within the 
context of a well-designed trial has been widely debated.38 Early salpingectomy has also 
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been proposed as an alternative initial step (with a delayed oophorectomy in the 
menopause as a second step) for high risk women who want to avoid detrimental 
consequences of premature menopause17. Premature menopause itself is associated with a 
3.03% increase in cardiovascular mortality, sexual dysfunction and osteoporosis.39 A recent 
systematic review highlights the limited and low-quality of available evidence on level of OC-
risk reduction and ovarian function associated with salpingectomy, with the large 
retrospective studies being limited by indication and detection bias.40 There has been lack of 
clarity on a number of issues, namely the level of risk reduction, the long-term impact of 
salpingectomy on ovarian function or onset of premature menopause and the issues of cost-
effectiveness of this approach.  
 
Our results suggest fimbrial tissue persists on the ovarian surface despite salpingectomy. 
This could play a role in ovarian carcinogenesis and be one of the reasons why 
salpingectomy does not prevent all epithelial OC.  These data further highlight the 
importance and need for well-designed prospective trials/research to define more precisely 
the level of benefit of reduction in ovarian cancer risk obtained from salpingectomy as a 
surgical prevention strategy. This is required for both the low and high risk populations. This 
is essential to understand the balance of risks and harms of this intervention so that women 
can make properly informed decisions on whether or not to undergo this procedure.  
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Table 1. Indication for surgery 
 
Indication n (%) 
21 
 
Menorrhagia 8/25 (32.0) 
Pelvic mass 2/25 (8.0) 
Ovarian cyst 4/25 (16.0) 
Pelvic pain 1/25 (4.0) 
Postmenopausal bleeding 4/25 (16.0) 
*Others  6/25 (24.0) 
*2 cases of confirmed cervical cancer (case number 14 and 21 see table-2), 3 cases of complex atypical 
hyperplasia (case number 11, 23 and 25 see table -2), 1 case of risk-reducing salpingo-oophorectomy for BRCA 
2 (case number 24 see table-2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2- Summary of all surgical cases 1 
Case 
No. 
Age  Menopausal 
status 
Indication for 
surgery/ 
Preoperative 
diagnosis 
Procedure 
undertaken 
Final Pathology Stage (if 
malignant) 
Adnexae 
included 
in 
analysis 
Intraoperative 
adhesions 
Residual 
fimbrial 
tissue on 
ovarian 
surface  
1 52 Pre-
menopausal 
Menorrhagia Laparotomy 
TAHBSO 
Benign leiomyoma n/a Both No Yes (left) 
2 50 Pre-
menopausal 
Menorrhagia Laparotomy 
subtotal 
hysterectomy + 
BSO 
Benign leiomyoma n/a Both No No 
3 56 Post-
menopausal 
Right ovarian cyst 
(benign) 
Laparoscopic 
BSO 
Simple serous cyst right ovary n/a Left No No 
4 52 Pre-
menopausal 
Menorrhagia Laparotomy 
TAHBSO 
Benign leiomyoma n/a Both No Yes (left) 
1 
 
5 53 Pre-
menopausal 
Pelvic pain, 
fibroid uterus 
Laparotomy 
TAHBSO 
Leiomyomata n/a Both No No 
6 59 Post-
menopausal 
Left ovarian mass 
(benign) 
Laparoscopic 
BSO 
Left ovarian fibroma n/a Right No No 
7 52 Pre-
menopausal 
Menorrhagia Laparotomy 
TAHBSO 
Benign leiomyoma n/a Both No No 
8 63 Post-
menopausal 
Benign 
endometrial 
biopsy but 
persistent PMB 
Laparotomy 
TAHBSO 
High grade mixed undifferentiated 
and endometriod carcinoma with 
LVSI (unexpected finding) 
Ib Both No No 
9 55 Post-
menopausal 
Benign 
endometrial 
biopsy but 
persistent PMB 
TLHBSO Grade 1 endometriod endometrial 
carcinoma with MELF pattern 
(unexpected finding) 
2 Right No No 
10 50 Pre-
menopausal 
Menorrhagia Laparotomy 
TAHBSO 
Adenomyosis, leiomyomata, non-
atypical hyperplasia 
n/a Left No No 
11 54 Post- Complex atypical TLHBSO Adenomyosis. Right ovarian n/a Both Yes (dense No 
2 
 
menopausal hyperplasia on 
endometrial 
biopsy 
endometriosis and benign serous 
adenofibroma 
adhesion right 
fimbriae & 
ovary) 
12 55 Post-
menopausal 
Right ovarian 
mass (benign) 
Laparotomy 
TAHBSO 
Fibroma - right ovary, serous 
cystadenomas and adenofibroma - 
left ovary + benign paratubal cysts 
bilaterally.  
n/a Right No No 
13 61 Post-
menopausal 
Right ovarian 
mass (benign) 
Laparoscopic 
BSO 
Hilar cell hyperplasia - left ovary, 
mature cystic teratoma - right ovary 
and tube 
n/a Left No No 
14 45 Pre-
menopausal 
Adenocarcinoma 
of cervix 
Laparoscopic 
radical 
hysterectomy + 
BSO 
Viloglandular adenocarcinoma of 
cervix with LVSI 
1b1 Both No No 
15 64 Post-
menopausal 
Left ovarian cyst Laparoscopic 
BSO 
Benign serous cyst – left ovary n/a Right No No 
16 50 Pre- Menorrhagia LAVH + BSO Adenomyosis n/a Both No No 
3 
 
menopausal 
17 55 Post-
menopausal 
Benign 
endometrial 
biopsy but 
persistent PMB 
Laparotomy 
TAHBSO 
Grade 3 endometriod endometrial 
carcinoma with LVSI 
2 Both No Yes (left) 
18 55 Post-
menopausal 
Left ovarian mass 
(benign) 
Laparotomy 
TAHBSO 
Dermoid - left ovary n/a Right No No 
19 62 Post-
menopausal 
Grade 1 
endometrioid 
endometrial 
cancer (stage 1A 
on MRI) 
Laparotomy 
TAHBSO 
Grade 1 endometriod endometrial 
carcinoma with focal LVSI 
1b Both No Yes (left) 
20 52 Pre-
menopausal 
Menorrhagia Laparotomy 
TAHBSO 
Benign leiomyoma n/a Both No No 
21 59 Post-
menopausal 
Grade 1 
squamous cell 
carcinoma of 
Laparoscopic 
radical 
hysterectomy 
Well differentiated squamous cell 
carcinoma of cervix 
1b1 Both No No 
4 
 
 2 
cervix and BSO 
22 56 Pre-
menopausal 
Menorrhagia Laparotomy 
TAHBSO 
Adenomyosis, benign leiomyomata n/a Right No No 
23 55 Post-
menopausal 
Complex atypical 
hyperplasia on 
endometrial 
biopsy 
TLHBSO Atypical hyperplasia n/a Both No No 
24 45 Pre-
menopausal 
Risk-reducing 
surgery for BRCA 
2 mutation 
Laparoscopic 
BSO 
Benign ovaries and tubes n/a Both Yes (dense 
adhesion left 
tube/fimbriae 
and ovary) 
No 
25 59 Post-
menopausal 
Complex atypical 
hyperplasia on 
endometrial 
biopsy 
LAVH + BSO Atypical hyperplasia n/a Both No No 
5 
 
TAHBSO = total abdominal hysterectomy and bilateral salpingo-oophorectomy, TLHBSO = total laparoscopic hysterectomy and bilateral salpingo-oophorectomy, LAVH/BSO 3 
= laparoscopic assisted vaginal hysterectomy and salpingo-oophorectomy, BSO = bilateral salpingo-oophorectomy, LVSI = Lymphovascular space invasion, MELF = 4 
microcystic elongated and fragmented, PMB = postmenopausal bleeding 5 
  6 
Figure caption and legends 
Figure-1: high grade serous carcinoma in fimbria adherent to ovarian surface 
High grade serous carcinoma (red arrow) in one of the fimbria (black arrows) adherent to 
the surface of the ovary. 
 
Figure-2: Fimbrial tissue implant on ovarian surface 
Fimbria (black arrows) adherent to the surface of the ovary. 
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